Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 154 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: incomplete Freund's adjuvant Clear all

Conditions: Melanoma (Skin)
Interventions: incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, cyclophosphamide; Biological · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 120 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Houston, Texas • Charlottesville, Virginia

Conditions: Prostate Cancer Recurrent
Interventions: RV001V, Placebo; Biological · Other
Lead sponsor: RhoVac APS; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more

Conditions: Prostate Specific Antigens, Prostate Neoplasms
Interventions: T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interferon alfa, sargramostim, tyrosinase peptide; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 32
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Decatur, Georgia + 24 more

Conditions: Unresectable or Metastatic Melanoma
Interventions: Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide, NY-ESO-1 OLP4 Vaccine with Poly-ICLC; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: New York, New York • Pittsburgh, Pennsylvania • Charlottesville, Virginia

Conditions: Tumors, Central Nervous System
Interventions: Montanide; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma
Interventions: gp100 human melanoma peptide; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG, poly ICLC, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions: PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: HIV-1 Immunogen; Biological
Lead sponsor: The Immune Response Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: HIV Infections
Interventions: Tetanus Toxoid Vaccine, Hepatitis A Vaccine (Inactivated), HIV-1 Immunogen, Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 2
States / cities: Iowa City, Iowa • New York, New York

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: OC-L/Montanide ISA 51 VG, Ampligen, Prevnar; Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma (Skin)
Interventions: aldesleukin, incomplete Freund's adjuvant, recombinant tyrosinase-related protein-2; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: aldesleukin, gp100 antigen, incomplete Freund's adjuvant, tyrosinase peptide; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: 6MHP, Montanide ISA-51, polyICLC, Cyclophosphamide; Biological · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma
Interventions: flt3 ligand, gp100 antigen, MART-1 antigen, Montanide ISA-51, tyrosinase peptide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Timeline: 1998 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine, incomplete Freund's adjuvant, sargramostim, immunoenzyme technique, immunologic technique; Biological · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: HIV Infections
Interventions: HIV-1 Immunogen; Biological
Lead sponsor: The Immune Response Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: 5-day TMZ, 21-day TMZ, PEP-CMV: Component A, Tetanus-Diphtheria booster, Tetanus Pre-Conditioning, PEP-CMV: Component B; Drug · Biological
Lead sponsor: Eric Thompson, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Extraocular Extension Melanoma, Recurrent Intraocular Melanoma
Interventions: gp100 antigen, interleukin-2, MART-1 antigen, Montanide ISA-51; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: OCPM Immunotherapeutic Vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Melanoma
Interventions: MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions: tyrosinase peptide, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions: decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay; Drug · Biological · Other + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors

A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Vaccine Therapy in Treating Patients With Melanoma

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

Novel Adjuvants for Peptide-Based Melanoma Vaccines

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer